Abstract Antimicrobial peptides (AMPs), both synthetic and from natural sources, have raised interest recently as potential alternatives to antibiotics. Cyto-insectotoxin (Cit1a) is a 69-amino-acid antimicrobial peptide isolated from the venom of the central Asian spider Lachesana tarabaevi. The synthetic gene Cit1a fused with the enhanced green fluorescent protein (EGFP) gene was expressed as the EGFP-Cit1a fusion protein using a cysteine protease-deleted Bombyx mori nucleopolyhedrovirus (BmNPV-CP − ) bacmid in silkworm larva and pupa. The antimicrobial effect of the purified protein was assayed using disk diffusion and broth microdilution methods. The minimum inhibitory concentration of EGFPCit1a was also measured against several bacterial strains and showed similar antimicrobial activity to that of the synthetic Cit1a reported earlier. The EGFP-Cit1a fusion protein showed antibiotic activity toward gram-positive and gramnegative bacteria at the micromolar concentration level. These results show that active Cit1a can be produced and purified in silkworm, although this peptide is insecticidal. This study demonstrates the potential of active Cit1a purified from silkworms to use as an antimicrobial agent.
Introduction
The widespread of overuse and inappropriate use of antibiotics in medical practice inevitably leads to the emergence of resistant bacterial strains (Wright 2007) , and antibiotic resistance is increasing at a rate that far exceeds the pace of the development of new antibiotics (Giuliani et al. 2007 ). The emergence of multidrug-resistant strains of different pathogens makes the need for the discovery of new antimicrobial agents increasingly important (Aziz and Wright 2005; Hayakawa et al. 2012) . To overcome this problem, the development and adoption of new antibiotics are required. Antimicrobial peptides (AMPs), both synthetic and native forms, have raised interest as antimicrobial agents (Giuliani et al. 2007 ). Among the potential candidates for new antimicrobial agents, AMPs deserve special attention (Yount and Yeaman 2012; Hancock and Sahl 2006) . AMPs are small polypeptide molecules (Yeaman and Yount 2003) and are found in a broad spectrum of organisms, from bacteria to vertebrates. AMPs most likely belong to the most ancient defense systems of multicellular organisms. Natural AMPs have been isolated from different organisms, ranging from bacteria to higher eukaryotes (Lazarev et al. 2011) . In most cases, AMPs are believed to directly bind to target cell membranes at micromolar concentrations, which lead to functional and/or structural disturbance of the cell membrane; this mechanism implies a low probability of bacteria acquiring resistance to AMPs (Yeaman and Yount 2003) .
In particular, spider venoms may concurrently contain several dozen AMPs with different structures and consequently, possess a broad spectrum of activity (Kozlov et al. 2006; Vassilevski et al. 2008 Vassilevski et al. , 2009 . Recently, Vassilevski et al. (2008) identified cyto-insectotoxin (Cit1a), a novel AMP from the venom of the Central Asian spider (Lachesana tarabaevi), which represents a unique class of spider venom constituents. Cit1a is a linear cationic peptide with 69 amino acid residues and represents an attractive molecule to combat intracellular pathogens as Cit1a has shown high antibacterial activity and a significant decrease in Chlamydia trachomatis viability inside infected cells (Polina et al. 2012 ). Lazarev et al. (Polina et al. 2012; Lazarev et al. 2013 ) characterized Cit1a as an antimicrobial and insecticidal peptide. Cit1a has low toxicity as shown by negligible toxicity to HEK293 cells and suppressed Chlamydia infection in the HEK293 cell line. Therefore, Cit1a is a potential agent for gene therapy for Chlamydia infection (Lazarev et al. 2011) . Cit1a has the potential to provide an important breakthrough and form the basis for a new class of antibiotics belonging to the linear amphipatic peptide class.
The wide range of Cit1a activity suggests that this peptide may be used as an antimicrobial and pesticidal agent in the future. Since AMPs are usually short peptides, chemical synthesis could be one approach for producing them. However, a cost-effective and scalable method for large-scale production is required in order to commercialize the AMP (Ramos et al. 2013) . AMPs can be prepared by solid phase peptide synthesis (Merrifield 1963) , although to produce peptides in this manner involves significant synthesis costs, particularly for large-scale purposes (Wang et al. 2011) . Preparative isolation of AMPs from natural sources and chemical synthesis is not economical (Hancock and Sahl 2006) . Recombinant production systems would enable the production of peptides and proteins in various expression systems and allow for the large-scale production of AMPs to be economically viable. Antimicrobial peptides are produced as a fusion protein in heterologous hosts to neutralize their innate toxic activity and increase their expression levels (Wang et al. 2011) . Large quantities of AMPs are required for pharmaceutical applications (Fan et al. 2010) . Numerous expression systems currently have been used for the economical production of antimicrobial peptides (Ingham and Moore 2007) .
Silkworm (Bombyx mori) is one of the most promising systems used for the production of recombinant AMPs (Liu et al. 2013; Fukushima et al. 2013) . Recombinant proteins and peptides have been successfully produced in silkworm larvae or pupae and have been used for academic and industrial purposes, with several recombinant proteins having already been commercialized (Kato et al. 2010) . There have been two systems, Bombyx mori nucleopolyhedrovirus and transgenic systems, which used silkworms for recombinant protein expression (Kato et al. 2010; Tomita 2011) . In this study, we used the silkworm in Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid system, for the expression and production of an AMP (Cit1a) which could potentially be used as a therapeutic agent for Chlamydia infection and as a potential pesticide. Enhanced green fluorescent protein (EGFP), which has no antimicrobial activity, was fused with Cit1a for expression in silkworms.
Materials and methods

Construction of recombinant BmNPV bacmid
The oligonucleotide sequences of Cit1a (accession number FM165474) was purchased from Eurofins MWG Operon (Tokyo, Japan), and the Cit1a gene was amplified by polymerase chain reaction (PCR) using the primer set FLAGCit1a-F and Cit1a-xba-R (Table 1 , primers 1 and 2). The EGFP fragment was also amplified as a DNA template from HPV174-EGFP Escherichia coli BmDH10Bac (Palaniyandi et al. 2013) by PCR using the primer set Eco-EGFP-F and EGFP-FLAG-R (Table 1 , primers 3 and 4). Each amplified /EGFP-Cit1a bacmid, together with a helper plasmid, were mixed with 1/10 volume of 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE-C) reagent (Life Technologies) and incubated at room temperature for 30 min. This mixture (10 μg of DNA, 50 μl) was injected into the abdominal section of the silkworm pupa with a needle (26 ga) and syringe. The DNA-injected silkworm pupae were incubated at 25°C in a humidified (65 %) environment for 4 to 6 days. The infected pupa was homogenated with Trisbuffered saline (TBS; pH 7.4) containing 0.1 % Triton X-100 (TBS-TX100) followed by sonication, and the homogenate was stored at −80°C until use. For silkworm larva, 50 μl of pupae homogenate diluted with phosphate-buffered saline (PBS; pH7.4) by 25 times was injected into each larva. The injected silkworm larvae were reared using Silkmate 2S (NOSAN Co., Yokohama, Japan) as a diet at 25°C in a humidified (65 %) environment for 3 to 5 days, followed by collection of the hemolymph and fat body from the silkworm larvae. Collected hemolymph and fat body were also stored at −80°C until use.
Confocal laser scanning microscopy
Small pieces of fat body were collected from rBmNPV-CP − / EGFP-Cit1a bacmid-injected silkworm larva and pupa for detecting the expressed EGFP-Cit1a fusion protein. The samples were taken from both rBmNPV-CP − /EGFP-Cit1a bacmid-injected and mock (control) silkworm larva and pupa. All samples were washed three times with PBS, and the cells were permeabilized using 0.1 % Triton X-100 in PBS for 20 min. The cells were stained with 4,6-diamidino-2-phenylindole (DAPI). Fluorescence was detected using a confocal laser scanning microscope (LSM 700, Zeiss, Jena, Germany), and images were analyzed by Zen 2010 software.
SDS-PAGE and Western blot analysis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot were carried out according to previously published methods (Palaniyandi et al. 2013) . For Western blot, mouse anti-FLAG M2 antibody (Sigma-Aldrich Japan, Tokyo, Japan) was used as the primary antibody to detect the EGFP-Cit1a fusion protein at 1:10,000 dilution. Sheep antimouse IgG antibody (GE Healthcare Japan, Tokyo, Japan) was used as the secondary antibody at a 1:10,000 dilution.
Protein concentration was measured using the BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA).
Purification of EGFP-Cit1a fusion protein from silkworm larvae and pupae
The fat bodies collected from ten silkworm larvae were suspended in 25 ml of ice-cold TBS buffer (pH 7.4) and lysed by sonication three times for 30 s each time with 1-min intervals. For silkworm pupae, ten pupae were homogenized with TBS Triton X-100 (0.1 %) followed by sonication. The sample was then centrifuged at 20,000g for 20 min, and the supernatant was filtered using a 0.45 μm filter. The collected filtrate was used for affinity purification using anti-DDDDK-tagged protein purification gel (Medical and Biological Laboratories Co., LTD, Nagoya, Japan). The anti-DDDDK-tagged protein purification gel was equilibrated with TBS buffer prior to use. The collected supernatant was mixed with 1 ml of gel and gently stirred at 4°C for 1 h. This mixture was centrifuged at 2,500g for 5 min, and the precipitated resin was washed with 36 ml of TBS buffer. Proteins bound to the resin were eluted with elution buffer (0.1 M glycine, pH 3.5). The purified protein was detected and confirmed using Coomassie brilliant blue (CBB) staining and Western blot analysis. The EGFP was removed from the EGFPCit1a fusion protein using recombinant entrokinase (rEK; Novagen, Darmstadt, Germany) according to the manufacturer's instructions. Fifty micrograms of purified fusion protein sample was digested with 1 unit of rEK at room temperature for 16 h. The product was analyzed by SDS-PAGE.
Mass spectrometry analysis
The molecular mass of the EGFP-FLAG-tagged Cit1a was determined by SDS-PAGE and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectroscopy. The MALDI-TOF mass spectrum was acquired on an AutoFlex (Bruker Daltonics, Germany) and measured in linear mode using 20-kV ion acceleration without postacceleration. The spectrum was recorded at a detector voltage of 1.65 kV and was the averaged result of at least 300 laser shots. The matrix was 2-hydroxy-5-methoxybenzoic acid (sDHB). The sample was dissolved in 0.1 % trifluoroacetic acid (TFA): acetonitrile (2:1v/v) and mixed with the matrix solution (1:4v/v). The mixture (1 μl) was put on a stainless target and crystallized at room temperature. A mass calibration procedure was employed prior to the analysis of a sample using protein calibration standards II (Bruker Daltonics, Germany).
Antimicrobial assays
The antimicrobial effect of EGFP-Cit1a was investigated using disk diffusion and broth microdilution methods, which are the standard methods recommended by the Clinical and Laboratories Standards Institute (CLSI) for measuring in vitro susceptibility of bacteria to antimicrobial agents used in clinical settings (CLSI 2009) . Although disk diffusion is the most popular method used to examine the antimicrobial activity of natural antimicrobial agents (Kim and Kim 2007; Mayachiew et al. 2010) , the foremost disadvantages of this method are the inability to measure the minimal inhibitory concentration (MIC) value and the difficulty in examining the susceptibility of fastidious and slow-growing bacteria (Wilkins and Thiel 1973; Dickert et al. 1981) . Moreover, unlike antimicrobial agents used in clinical settings, there are currently no standard CLSI interpretive criteria of disk diffusion results to support natural antimicrobial susceptibility testing. Thus, disk diffusion is unable to explain the zone diameter that it generates for natural antimicrobials (Jiang 2011) . For these reasons, we used two standard methods in this study: the microdilution method for measuring the MIC values and the disk diffusion method for visualization of the inhibitory effects of EGFP-Cit1a against bacteria.
For the disk diffusion method, the bacterial inoculum was adjusted to~10 5 colony-forming units (CFU)/ml and inoculated onto the entire surface of a Luria-Bertani (LB) agar plate. The paper disks (BD Diagnostic Systems, NJ, USA) were impregnated in 6-mm diameter circles with 12 μl diluted EGFP-Cit1a solutions and placed on the LB agar plate. The plates were then incubated aerobically overnight at 37°C, and subsequently, the inhibition zone was observed. A series of diluted EGFP-Cit1a solution in PBS was used, including a positive control using ampicillin for gram-negative bacteria and chloramphenicol for gram-positive bacteria. Bacillus subtilis (NBRC13719, NITE, Kisarazu-shi, Chiba, Japan) and Staphylococcus aureus (NBRC 100910, NITE) as grampositive and Pseudomonas aeruginosa (NBRC12689, NITE) and E. coli W3110 (NBRC12713) as gram-negative were kind gifts from Professor Shinya Kotani.
MIC determination of EGFP-Cit1a was performed using a microtiter broth dilution assay as described by Vassilevski et al. (2008) . In this method, antimicrobial activity was conducted with a bacterial strain in sterilized 96-well plates in a final volume of 100 μl composed of 50 μl of suspension containing 10 5 bacteria/ml in LB culture medium and 50 μl of the peptide in serial twofold dilutions in PBS. Midexponential phase cultures were diluted to a final concentration of 10 5 CFU/ml. Fifty microliters of purified rEGFPCit1a was added to 50 μl of the diluted bacterial suspension (~10 5 CFU/ml). The peptides, a non-treated control with PBS, a positive control with ampicillin or chloramphenicol, and a negative control with BSA were tested in triplicate. The microtiter plates were incubated overnight at 37°C, and the inhibition of growth was determined by measuring the absorbance at 595 nm. MIC is expressed as the lowest concentration of peptide that causes 100 % growth inhibition .
Results
Construction of an expression recombinant BmNPV bacmid
To express the Cit1a from L. tarabaevi in silkworms, EGFPCit1a fusion protein was expressed according to Fig. 1a . Cit1a was fused to EGFP as a reporter gene by PCR through the FLAG-tag sequence, which was checked by agarose gel electrophoresis (Fig. 1b) . The fusion gene was successfully cloned into the transfer vector (pFastBac1) (Fig. 1a) . The generated recombinant pFastBac1-Cit1a was verified by amplifying the target region using PCR and sequencing (data not shown). The recombinant pFastBac1-Cit1a was transformed into an E. coli BmDH10Bac competent cell, and finally, recombinant BmNPV-CP − /EGFP-Cit1a bacmid was constructed.
Expression of EGFP-Cit1a fusion protein from silkworm larvae and pupae For the expression and purification of the fusion protein, recombinant BmNPV-CP − /EGFP-Cit1a bacmid was prepared and injected into silkworm larvae and pupae. After 4 to 6 days, fat bodies collected from the infected larvae were suspended in TBS and sonicated to extract the expressed EGFP-Cit1a fusion protein. BmNPV-CP − /EGFP-Cit1a bacmid-injected pupae were also homogenized with TBS. The specific EGFP fluorescent band on SDS-PAGE was observed in the homogenate of the BmNPV-CP − /EGFP-Cit1a bacmidinjected pupal and larval fat bodies but not in the larval hemolymph and mock-injected fat body (Fig. 1c) . In addition, the expressed EGFP-Cit1a fusion protein was confirmed in Western blot analysis (Fig. 1d) . The theoretical molecular weight of the GFP-Cit1a fusion protein was~36 kDa, which is similar to the detected molecular weight of the fusion protein, and no band was observed from the mock-injected silkworm (Fig. 1d) . Confocal laser scanning microscopy was also used to further confirm the expressions of the EGFP-Cit1a fusion protein in silkworm larvae and pupae. EGFP fluorescence was observed in the larval (Fig. 2a) and pupal fat bodies (Fig. 2c) of the silkworm. Mock-infected silkworm larvae and pupae did not show any EGFP fluorescence (Fig. 2b, d ).
The expressed EGFP-Cit1a fusion protein was purified from the fat bodies of the silkworm larvae and pupae using DDDDK-tagged purification gel. This purification gel facilitates the purification of FLAG-tagged proteins equally to anti-FLAG M2 agarose gel. Several proteins tagged with FLAG have been shown to be successfully purified using this gel Table 1 . b Agarose gel electrophoresis of PCR products in PCR steps (PCR 1-3). Lane 1 PCR 1, lane 2 PCR 2, lane 3 PCR 3. c EGFP fluorescence analysis of the EGFP-Cit1a fusion protein expressed in silkworm on an SDS-PAGE gel. Lanes 1, 3, and 5 show the homogenates of BmNPV-CP − /EGFP-Cit1a bacmid-injected pupa, larval hemolymph, and fat body, respectively; lanes 2 and 4 show the homogenates of mock-injected pupa and larval hemolymph, respectively; and lane 6 shows the mock-injected larval fat body. Fluorescent bands were detected using Molecular Imager FX (Bio-Rad) indicated by arrows. d Western blot analysis of EGFPCit1a fusion protein cross-reacted with antibodies is indicated by arrows. Lane 1 shows the mock pupa homogenate; lanes 2, 4, and 6 show the BmNPV-CP − /EGFP-Cit1a bacmid-injected larval fat body, hemolymph, and pupa homogenate, respectively; lanes 3 and 5 show the mock larval hemolymph and fat body, respectively (Deo et al. 2014) . A single band was detected by CBB staining and Western blot (Fig. 3a) in the eluted fraction of the BmNPV-CP − /EGFP-Cit1a bacmid-injected larvae's fat body. In the same manner, purified samples (elution 1~3 of BmNPV-CP − /EGFP-Cit1a bacmid-injected pupa's homogenate) showed a single band in CBB staining and Western blot (Fig. 3b) . In SDS-PAGE analysis, the band of EGFP-Cit1a was detected below 37 kDa (Fig. 3) . The molecular weight of the EGFP-Cit1a fusion protein, calculated from its amino acid sequence, is 36.067 kDa. In a previous paper, Cit1a has a 60 % alpha-helix structure in 25-mM SDS solution , suggesting that Cit1a has its native conformation in the sample buffer of SDS-PAGE to some extent, and its structure may cause the difference between the molecular weight estimated from its amino acid sequence and that detected by the SDS-PAGE. In addition, this protein purified from BmNPV-CP − /EGFP-Cit1a bacmid-injected larvae's fat body was investigated by MALDI-TOF mass analysis. The MALDI-TOF mass spectrum demonstrated a main peak at m/z 37338 (Fig. 4) . Another peak was detected at m/z 28622. This low molecular weight corresponded to that of EGFP tagged with the FLAG sequence estimated from its amino acid sequence (28197). However, no band was observed in the SDS-PAGE or Western blot. These data suggest that this low molecular weight peak might be caused during the MALDI-TOFMS experiment, or it may be possible that the purified protein still contained a significant amount of contaminated proteins. Around the peak at m/z 37338, several peaks were also detected which formed a broad peak. These data also suggest that the purified EGFP-Cit1a fusion protein had several variants. Spider peptide toxins are sometimes posttranslationally modified by palmitoylation, C-terminal trimming, and C-terminal amidation (Windley et al. 2012 ). C-terminal amidation was not detected in the native Cit1a ; therefore, it is most reasonable that the EGFP-Cit1a heterogeneity may be caused by C-terminal trimming.
To confirm the fusion of Cit1a with EGFP via the FLAGtagged sequence, the purified fusion protein was treated with rEK, and the difference between the molecular weights of the rEK-treated and non-treated samples were investigated in SDS-PAGE. rEK recognizes the DDDDK sequence in the FLAGtagged sequence and can cleave the EGFP-Cit1a fusion protein into EGFP-FLAG and Cit1a. The rEK-treated fusion protein showed two bands (~27 and~8 kDa) (Fig. 5) . The rEK digestive experiment confirmed that Cit1a was expressed fused with EGFP in the silkworm and could be separated from EGFP. The expression level between the silkworm larval fat body and pupa was compared in Western blot analysis. The amount of purified EGFP-Cit1a fusion protein was 10 μg/pupa from pupal fat body and 7 μg/larva from the larval fat body. In this study, EGFP was adopted as a fusion partner of Cit1a, and the functional analysis of EGFP-Cit1a purified from silkworm fat body was performed in the next section.
Antimicrobial activity of Cit1a
Extensive biological studies were performed only for the synthetic Cit1a, which was tested on a number of grampositive and gram-negative bacteria, and approximate MIC (low micromolar against E. coli) values were determined for the peptide (Lazarev et al. 2011 (Lazarev et al. , 2013 Polina et al. 2012; Vassilevski et al. 2008) . The antimicrobial activity of Cit1a was evaluated using purified EGFP-Cit1a fusion protein, based on the clear inhibition zone surrounding the paper disks. A clear inhibition zone was observed in E. coli W3110, B. subtilis, and P. aeruginosa bacterial growth (Fig. 6a, c, d ). However, no inhibition zone was found in S. aureus (Fig. 6b) .
The MIC values were determined by a microdilution method. The MIC results indicated that E. coli W3110, B. subtilis, and P. aeruginosa were inhibited by the recombinant Cit1a at low concentrations (0.75-2.00 μM) ( Table 2 ). The MIC value of E. coli W3110 was 0.75 μM. Below 0.75 μM, the growth inhibition was decreased (data not shown).
Discussion
Spider venoms represent an attractive source of peptides with a variety of different types of bioactivity, representing vast natural resources (Kuhn-Nentwig et al. 2011; Liang 2008; Vassilevski et al. 2009 ). Cit1a identified from spider venom having equally potent antimicrobial and insecticidal effects (Vessilevski et al. 2008 ) was expressed and produced using silkworm.
In this study, EGFP was fused with Cit1a to mask Cit1a activity. In a previous report, when GFP uv fusion protein was expressed in silkworm larvae, several degraded fusion proteins appeared ). EGFP-Cit1a was not significantly degraded in silkworms even if Cit1a was fused with EGFP. This indicated that the EGFP-Cit1a fusion protein was not vulnerable to proteases in silkworms. In addition, the EGFP-Cit1a fusion protein was not observed in the hemolymph (Fig. 1c, d ), because EGFP-Cit1a does not have any signal sequence at its N-terminus. Cit1a does natively possess a signal sequence and pro-domain; however, in this study, these sequences were removed to fuse with EGFP at the Nterminus of Cit1a.
The production of recombinant proteins using the silkworm depends on the properties of protein. The expression level of Cit1a was lower, compared to other proteins (Kato et al. 2010) , but this system provides rapid production of recombinant protein. AMPs have often been produced in various expression systems as fusion proteins with carrier proteins, such as glutathione-S-transferase (GST), protein A, and maltose-binding protein (MBP), to increase the AMP solubility and mask the antimicrobial activity for expression (Kozlov et a. 2008) . Originally, this Cit1a peptide possesses insecticidal activity ), but active Cit1a was expressed in silkworms. In a previous report, this Cit1a did not have cytotoxic effects on the host cell when expressed intracellularly in HEK293 cells (Lazarev et al. 2011 ). We presumed that this peptide also may not be toxic to insect cells when expressed intracellularly. Silkworm expression system can be used for the large-scale production of Cit1a and other linear peptide toxins through intracellular expression. Cit1a obtained from this study showed antimicrobial effect on E. coli W3110, B. subtilis, and P. aeruginosa (Fig. 6a, c, d ), but there was no effect on S. aureus (Fig. 6b) . A previous study reported that synthetic Cit1a showed no inhibitory effect on S. aureus (Kozlov et al. 2008) , which is similar to the results obtained in our study. These approaches demonstrate that the recombinant protein produced in silkworm is active against bacteria, as reported previously (Chen et al. 2009; Kozlov et al. 2008) , and the MIC value (Table 2) falls within the MIC values of other peptides (Kozlov et al. 2008) . Moreover, the MIC values of EGFP-Cit1a against E. coli, P. aeruginosa, and B. subtilis were comparable with those in a previous report , indicating that the EGFP and FLAG tag do not have any negative influence on the properties of Cit1a. Also, these data suggest that the EGFP-Cit1a fusion protein can be used directly without cleavage by EK and silkworm larvae can produce active Cit1a in its fat body. Cit1a has cytotoxicity to Sf-9 cells and has been known as an insecticidal peptide . These results show the contradiction that an active insecticidal peptide can be expressed and purified in insects. However, Cit1a can be expressed in HEK293 cells as an active form to suppress the infection of a parasitic bacterium, Chlamydia (Lazarev et al. 2011 (Lazarev et al. , 2013 Polina et al. 2012) . These data suggest that Cit1a can be expressed as an active form intracellularly without cytotoxicity to host cells. Moreover, EGFP fusion proteins have been utilized for the intracellular trafficking and functional analysis of expressed proteins in vivo (Avilov et al. 2013; Sammons and Gross 2013) . EGFP-Cit1a fusion protein allows us to analyze the intracellular trafficking of Cit1a in Chlamydia and its suppression mechanism.
Although we used the EGFP-Cit1a fusion protein to test for biological activity against bacteria, it was confirmed that the growth inhibition of bacteria happened due only to the action of the Cit1a gene because the EGFP gene has no toxic effects on the cell (Chalfie et al. 1994) . Cit1a is active at low micromolar concentrations, although a certain specificity of action was shown, with some bacteria essentially resistant to the peptide (Kozlov et al. 2008) . The properties, wide spectrum of activity at micromolar concentration, and membrane specificity are common to most of other AMPs. These phenomena are described by the approved universal mechanism of AMP action with the plasma membrane serving as the target (Kozlov et al. 2008) . Biologically active recombinant fusion protein could be obtained from both silkworm larvae and pupae, indicating that silkworm can produce soluble Cit1a to characterize it. The development of cost-effective systems for peptide production with recombinant DNA technology is of great interest due to the increasing use of peptides as pharmaceutical agents. AMPs have also been shown to repress mycoplasma and Chlamydia development in vitro (Fehri et al. 2007; Yasin et al. 1996) . However, active peptide concentrations are usually 0.1 to 10 μM, corresponding to rather high therapeutic doses.
In the present paper, we expressed and produced Cit1a as an EGFP-Cit1a fusion protein using silkworm and investigated the antimicrobial activity of Cit1a, a cytolytic peptide produced by L. tarabaevi which represents a unique class of spider venom constituents. Antimicrobial peptides have been studied extensively because of their potential clinical applications as pharmaceutical agents (Fan et al. 2010 ).
In conclusion, our study developed a new strategy for the expression and production of Cit1a using silkworm fused with the EGFP. For large-scale preparation of recombinant proteins, the BmNPV bacmid system-using silkworm could be used due to its low cost, ease of treatment, and high biohazard safety. The recombinant Cit1a showed high antimicrobial activity as previously reported, which makes Cit1a a promising candidate as a therapeutic.
